Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBFB | Q13951 | 6/20 | 0.55 |
| ▸ | DHODH | Q02127 | 4/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 6/20 | 0.41 |
| ▸ | SYK | P43405 | 2/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4174460 | 0.87 | CBFB (0.62) | CBFBDHODHCACNA1HSYKCACNA1G | |
| SCHEMBL4187103 | 0.85 | CBFB (0.60) | CBFBCACNA1HSYKCACNA1GCACNA1C | |
| SCHEMBL15981090 | 0.84 | CBFB (0.75) | CBFBCACNA1HSYKCACNA1GCACNA1C | |
| SCHEMBL4176876 | 0.83 | CBFB (0.71) | CBFB | |
| SCHEMBL16121153 | 0.81 | CACNA1H (0.51) | CBFBCACNA1HCACNA1GCACNA1CCACNA1B | |
| SCHEMBL4193080 | 0.78 | DHODH (0.42) | CBFBDHODHCACNA1HCACNA1GCACNA1C | |
| SCHEMBL4192523 | 0.77 | CBFB (0.55) | CBFBDHODH | |
| SCHEMBL4182080 | 0.76 | METAP2 (0.69) | CBFBSYK | |
| SCHEMBL4186602 | 0.75 | CBFB (0.82) | CBFBDHODH | |
| SCHEMBL4180008 | 0.74 | TRPV1 (0.54) | CBFBCACNA1HCACNA1GCACNA1CCACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9199965-B2 | Benzoimidazole derivatives and pharmaceutical composition comprising the same | DAEWOONG CO., LTD. (KR) | 2015-12-01 | — | — | US | claimed |
| US-20090018124-A1 | Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-01-15 | — | — | US | claimed |
| US-9199965-B2 | Benzoimidazole derivatives and pharmaceutical composition comprising the same | DAEWOONG CO., LTD. (KR) | 2015-12-01 | — | — | US | disclosed |
| US-9199965-B2 | Benzoimidazole derivatives and pharmaceutical composition comprising the same | DAEWOONG CO., LTD. (KR) | 2015-12-01 | — | — | US | disclosed |
| US-9199965-B2 | Benzoimidazole derivatives and pharmaceutical composition comprising the same | DAEWOONG CO., LTD. (KR) | 2015-12-01 | — | — | US | disclosed |
| US-20090018124-A1 | Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-01-15 | — | — | US | disclosed |
| US-20090018124-A1 | Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-01-15 | — | — | US | disclosed |
| US-20090018124-A1 | Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018124-A1 | Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same | TRPV1, TRPA1, BDKRB2 | CBFB 1891/4885DHODH 1246/4885CACNA1H 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.